{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:10:24Z","timestamp":1771560624413,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ijrobp.2016.10.011","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T17:47:31Z","timestamp":1476985651000},"page":"462-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer"],"prefix":"10.1016","volume":"97","author":[{"given":"Michela","family":"Buglione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Maddalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Corv\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Pirtoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Paiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Lastrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Stefanacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Belgioia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Crociani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bertocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Pasinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Tonoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano Maria","family":"Magrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2016.10.011_bib1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-Year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2006.08.035","article-title":"Cetuximab combined with radiotherapy: An alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?","volume":"43","author":"Bernier","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/0019-509X.82872","article-title":"Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?","volume":"48","author":"Agarwal","year":"2011","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: A randomized phase II trial","volume":"34","author":"Magrini","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ijrobp.2010.07.008","article-title":"Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer","volume":"81","author":"Koutcher","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.oraloncology.2014.07.001","article-title":"Efficacy of concurrent cetuximab vs. 5-fluorouracil\/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC)","volume":"50","author":"Shapiro","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4103\/0973-1482.126455","article-title":"Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: Cisplatin versus cetuximab","volume":"9","author":"Ye","year":"2013","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000355194","article-title":"Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma","volume":"85","author":"Ley","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib11","unstructured":"Trotti A, Gillison M. Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01302834. Accessed March 15, 2016."},{"key":"10.1016\/j.ijrobp.2016.10.011_bib12","unstructured":"Mehanna H, Dunn J. Determination of epidermal growth factor\u00a0receptor-inhibitor (cetuximab) versus standard chemotherapy\u00a0(cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01874171. Accessed March 15, 2016."},{"key":"10.1016\/j.ijrobp.2016.10.011_bib13","unstructured":"Trans-Tasman Radiation Oncology Group. Weekly cetuximab\/RT versus weekly cisplatin\/RT in HPV-associated oropharyngeal squamous cell carcinoma (HPVOropharynx). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01855451. Accessed March 15, 2016."},{"key":"10.1016\/j.ijrobp.2016.10.011_bib14","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib15","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.2008.20.2853","article-title":"Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck","volume":"27","author":"Lassen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib16","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1200\/JCO.2015.64.7586","article-title":"Cisplatin versus cetuximab with radiotherapy in locally advanced squamous cell carcinoma of the head and neck","volume":"34","author":"Husain","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib17","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","article-title":"Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: Long-term report of efficacy and toxicity","volume":"32","author":"Nguyen-Tan","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.09.002","article-title":"Dose de-escalation in human papillomavirus-associated oropharyngeal cancer: First tracks on powder","volume":"93","author":"Yom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib19","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2015.08.033","article-title":"Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"93","author":"Chera","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib20","unstructured":"Yom SS. A randomized phase II trial for patients with p16 positive, non-smoking associated, locoregionally advanced oropharyngeal cancer. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02254278. Accessed March 15, 2016."},{"key":"10.1016\/j.ijrobp.2016.10.011_bib21","unstructured":"Harry Q, Forastiere A. A phase II study on treatment de-intensification in favorable squamous cell carcinoma of the oropharynx. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01088802. Accessed March 15, 2016."},{"key":"10.1016\/j.ijrobp.2016.10.011_bib22","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2007.12.7662","article-title":"EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer","volume":"26","author":"Kumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.radonc.2013.08.036","article-title":"Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: Correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials","volume":"108","author":"Lassen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib24","doi-asserted-by":"crossref","first-page":"e63440","DOI":"10.1371\/journal.pone.0063440","article-title":"Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes","volume":"8","author":"Maiti","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib25","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ejca.2013.12.018","article-title":"Oropharyngeal cancers: Relationship between epidermal growth factor receptor alterations and human papillomavirus status","volume":"50","author":"Mirghani","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib26","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.4314\/tjpr.v14i12.9","article-title":"Differences in expression of EGFR, Ki67 and p-EPK in oral cavity squamous cell carcinoma","volume":"14","author":"Bu","year":"2015","journal-title":"Trop J Pharm Res"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib27","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: Mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib28","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1200\/JCO.2015.62.5970","volume":"34","author":"Rosenthal","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib29","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","article-title":"Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib30","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1078-0432.CCR-03-1077","article-title":"Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy","volume":"10","author":"Argiris","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/11598190-000000000-00000","article-title":"Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: A meta-analysis","volume":"11","author":"Wang","year":"2011","journal-title":"Drugs R D"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12916-014-0203-5","article-title":"Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: A systematic review and meta-analysis","volume":"12","author":"Qi","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib33","doi-asserted-by":"crossref","first-page":"e50163","DOI":"10.1371\/journal.pone.0050163","article-title":"Infectious complications in head and neck cancer patients treated with cetuximab: Propensity score and instrumental variable analysis","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1756-9966-28-113","article-title":"Association of cetuximab with adverse pulmonary events in cancer patients: A comprehensive review","volume":"28","author":"Hoag","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.critrevonc.2015.03.003","article-title":"Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus","volume":"95","author":"Mirabile","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib36","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.10.011_bib37","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.2015.60.7804","article-title":"Human papillomavirus-negative pharyngeal cancer","volume":"33","author":"Dillon","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616333314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616333314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T10:56:13Z","timestamp":1536317773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301616333314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0360301616333314"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.10.011","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}